Renal Drug Handbook, fifth edition
- Product / population
- Historical 2019 reference; renal bands retain the book's own method labels.
- Renal measure
- Not specified; verify before use
- Source revision
- Not established
- Retrieved
- 2026-09-05 (not the revision date)
The current selected U.S. label contraindicates eGFR below 30. Do not apply the old 10-45 percentage row below that threshold. The handbook's normal-dose maximum of 3 g/day is not the selected U.S. IR maximum.
Historical table and internal limitation
The book's table lists 25-50% of normal dose, maximum 2000 mg/day, at GFR 45-59; 25% at 10-45; and avoidance below 10. However, its Other information explicitly states manufacturer contraindication below 30 and a 1000 mg/day maximum at 30-44. The broad 10-45 row is therefore NOT reproduced as a current treatment algorithm.
Renal replacement
The book recommends avoidance for APD/CAPD, HD, high-flux HDF and CAV/VVHD. It describes metformin removal by HD/high-flux treatment, probable removal by CAV/VVHD and uncertain peritoneal removal.
Source:
